Quantitative analysis of drug distribution in heterogeneous tissues using dual-stacking capillary electrophoresis-mass spectrometry

被引:4
作者
Koganemaru, Shigehiro [1 ]
Kawai, Takayuki [2 ,3 ,7 ]
Fuchigami, Hirobumi [4 ]
Maeda, Naoyuki [5 ]
Koyama, Kumiko [5 ]
Kuboki, Yasutoshi [1 ]
Mukohara, Toru [6 ]
Doi, Toshihiko [1 ]
Yasunaga, Masahiro [4 ]
机构
[1] Natl Canc Ctr Hosp East, Dept Expt Therapeut, Kashiwa, Japan
[2] Kyushu Univ, Fac Sci, Dept Chem, Fukuoka, Japan
[3] RIKEN Ctr Biosyst Dynam Res, Suita, Japan
[4] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Dev Therapeut, Kashiwa, Japan
[5] Daiichi Sankyo Co Ltd, Translat Sci Dept 1, Tokyo, Japan
[6] Natl Canc Ctr Hosp East, Dept Med Oncol, Kashiwa, Japan
[7] Kyushu Univ, Fac Sci, Fukuoka 8190395, Japan
关键词
antibody-drug conjugate; bystander effect; capillary electrophoresis-mass spectrometry; in situ tissue pharmacokinetic analysis; tumour heterogeneity; HER2-TARGETING ADC; TUMORS; EXPRESSION; CONJUGATE; DS-8201A;
D O I
10.1111/bph.15988
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and PurposeIntratumour heterogeneity frequently leads to drug resistance, which is a major issue in drug discovery. Drug distribution is one of the key factors for elucidating the resistance mechanism; however, quantitative and regional drug measurement is challenging. Here, we developed a novel ultra-sensitive analytical method and applied it to HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd), aiming to explore its payload (DXd) distribution within heterogeneous tissues. Experimental ApproachThe developed analytical method is named LDMS-CE-MS, a capillary electrophoresis-mass spectrometry (CE-MS) coupled with a novel sample preconcentration/separation method called "large-volume dual-sample stacking by micelle collapse and sweeping (LDMS)". First, the analytical performance of LDMS-CE-MS for DXd detection was evaluated. Subsequently, we evaluated the bystander effect of HER3-DXd, where tumour tissues were excised from xenograft models and clinical specimens after administration of HER3-DXd. HER3-high expression, adjacent, and HER3-low expression regions were then sampled by laser microdissection to quantify the released DXd. Key ResultsLDMS concentrated DXd by 1000-fold and separated it from the hydrophilic bio-matrix through continuous capture and release by the charged micelles, allowing quantification at sub-attomole-level. DXd concentrations decreased in the order of antigen-high expression > adjacent > antigen-low expression regions in the tumour xenograft model, whereas in clinical specimens, adjacent and antigen-high expression regions had approximately the same concentration. These distributions represent a bystander effect. Conclusions and ImplicationsOur LDMS-CE-MS successfully visualized the attomole-level drug distributions in heterogeneous clinical specimens. This new platform opens a new era of quantitative pharmacokinetic analysis, facilitating drug discovery and development.
引用
收藏
页码:762 / 774
页数:13
相关论文
共 39 条
[1]   Clinical development times for innovative drugs [J].
Brown, Dean G. ;
Wobst, Heike J. ;
Kapoor, Abhijeet ;
Kenna, Leslie A. ;
Southall, Noel .
NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (11) :793-794
[2]   Tumour heterogeneity and resistance to cancer therapies [J].
Dagogo-Jack, Ibiayi ;
Shaw, Alice T. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (02) :81-94
[3]   The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research [J].
du Sert, Nathalie Percie ;
Hurst, Viki ;
Ahluwalia, Amrita ;
Alam, Sabina ;
Avey, Marc T. ;
Baker, Monya ;
Browne, William J. ;
Clark, Alejandra ;
Cuthill, Innes C. ;
Dirnagl, Ulrich ;
Emerson, Michael ;
Garner, Paul ;
Holgate, Stephen T. ;
Howells, David W. ;
Karp, Natasha A. ;
Lazic, Stanley E. ;
Lidster, Katie ;
MacCallum, Catriona J. ;
Macleod, Malcolm ;
Pearl, Esther J. ;
Petersen, Ole H. ;
Rawle, Frances ;
Reynolds, Penny ;
Rooney, Kieron ;
Sena, Emily S. ;
Silberberg, Shai D. ;
Steckler, Thomas ;
Wuerbel, Hanno .
PLOS BIOLOGY, 2020, 18 (07)
[4]  
Eriksson Cecilia, 2013, Mass Spectrom (Tokyo), V2, pS0022, DOI 10.5702/massspectrometry.S0022
[5]   Spatial Heterogeneity in Drug Concentrations Can Facilitate the Emergence of Resistance to Cancer Therapy [J].
Fu, Feng ;
Nowak, Martin A. ;
Bonhoeffer, Sebastian .
PLOS COMPUTATIONAL BIOLOGY, 2015, 11 (03)
[6]   Imaging mass spectrometry for the precise design of antibody-drug conjugates [J].
Fujiwara, Yuki ;
Furuta, Masaru ;
Manabe, Shino ;
Koga, Yoshikatsu ;
Yasunaga, Masahiro ;
Matsumura, Yasuhiro .
SCIENTIFIC REPORTS, 2016, 6
[7]   Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect [J].
Golfier, Sven ;
Kopitz, Charlotte ;
Kahnert, Antje ;
Heisler, Iring ;
Schatz, Christoph A. ;
Stelte-Ludwig, Beatrix ;
Mayer-Bartschmid, Anke ;
Unterschemmann, Kerstin ;
Bruder, Sandra ;
Linden, Lars ;
Harrenga, Axel ;
Hauff, Peter ;
Scholle, Frank-Detlef ;
Mueller-Tiemann, Beate ;
Kreft, Bertolt ;
Ziegelbauer, Karl .
MOLECULAR CANCER THERAPEUTICS, 2014, 13 (06) :1537-1548
[8]   Phase II and phase III failures: 2013-2015 [J].
Harrison, Richard K. .
NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (12) :817-818
[9]   A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization [J].
Hashimoto, Yuuri ;
Koyama, Kumiko ;
Kamai, Yasuki ;
Hirotani, Kenji ;
Ogitani, Yusuke ;
Zembutsu, Akiko ;
Abe, Manabu ;
Kaneda, Yuki ;
Maeda, Naoyuki ;
Shiose, Yoshinobu ;
Iguchi, Takuma ;
Ishizaka, Tomomichi ;
Karibe, Tsuyoshi ;
Hayakawa, Ichiro ;
Morita, Koji ;
Nakada, Takashi ;
Nomura, Taisei ;
Wakita, Kenichi ;
Kagari, Takashi ;
Abe, Yuki ;
Murakami, Masato ;
Ueno, Suguru ;
Agatsuma, Toshinori .
CLINICAL CANCER RESEARCH, 2019, 25 (23) :7151-7161
[10]   Sheathless capillary electrophoresis-mass spectrometry with a high-sensitivity porous sprayer for cationic metabolome analysis [J].
Hirayama, Akiyoshi ;
Tomita, Masaru ;
Soga, Tomoyoshi .
ANALYST, 2012, 137 (21) :5026-5033